Vol 14, Supp. I (2020)
Editorial
Published online: 2020-12-30

open access

Page views 391
Article views/downloads 320
Get Citation

Connect on Social Media

Connect on Social Media

Zastosowanie tabletek fentanylu podawanych drogą podjęzykową w leczeniu bólu przebijającego (epizodycznego) u chorych na nowotwory

Wojciech Leppert
DOI: 10.5603/PMPI.2020.0044

Abstract

Not available

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Løhre ET, Klepstad P, Bennett MI, et al. European Association for Palliative Care Research Network. From "Breakthrough" to "Episodic" Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations. J Pain Symptom Manage. 2016; 51(6): 1013–1019.
  2. Davies AN, Dickman A, Reid C, et al. Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009; 13(4): 331–338.
  3. Narayana A, Katz N, Shillington AC, et al. National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes. Pain. 2015; 156(2): 252–259.
  4. Pietrzyński Ł, Włodarska M, Danikiewicz M, et al. Ocena i leczenie bólu przebijającego u chorych na nowotwory. Palliative Medicine in Practice. 2018; 12(3): 156–164.
  5. Brząkała J, Leppert W. The role of rapid onset fentanyl products in the management of breakthrough pain in cancer patients. Pharmacol Rep. 2019; 71(3): 438–442.
  6. Løhre ET, Thronæs M, Klepstad P. Breakthrough cancer pain in 2020. Curr Opin Support Palliat Care. 2020; 14(2): 94–99.
  7. Webber K, Davies AN, Zeppetella G, et al. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manage. 2014; 48(4): 619–631.



Palliative Medicine in Practice